BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29572391)

  • 1. Infusion of donor-derived CD8
    Muffly L; Sheehan K; Armstrong R; Jensen K; Tate K; Rezvani AR; Miklos D; Arai S; Shizuru J; Johnston L; Meyer E; Weng WK; Laport GG; Negrin RS; Strober S; Lowsky R
    Blood Adv; 2018 Mar; 2(6):681-690. PubMed ID: 29572391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
    Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD.
    Dutt S; Baker J; Kohrt HE; Kambham N; Sanyal M; Negrin RS; Strober S
    Blood; 2011 Mar; 117(11):3230-9. PubMed ID: 21239702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
    Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
    Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
    J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
    Nikiforow S; Kim HT; Daley H; Reynolds C; Jones KT; Armand P; Ho VT; Alyea EP; Cutler CS; Ritz J; Antin JH; Soiffer RJ; Koreth J
    Haematologica; 2016 Oct; 101(10):1251-1259. PubMed ID: 27354021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells.
    Müller N; Landwehr K; Langeveld K; Stenzel J; Pouwels W; van der Hoorn MAWG; Seifried E; Bonig H
    Cytotherapy; 2018 Apr; 20(4):532-542. PubMed ID: 29500069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
    Soiffer RJ; Alyea EP; Hochberg E; Wu C; Canning C; Parikh B; Zahrieh D; Webb I; Antin J; Ritz J
    Biol Blood Marrow Transplant; 2002; 8(11):625-32. PubMed ID: 12463482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-reactive CD8+ memory stem cells in graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    Nat Med; 2005 Dec; 11(12):1299-305. PubMed ID: 16288282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
    Fowler DH; Mossoba ME; Steinberg SM; Halverson DC; Stroncek D; Khuu HM; Hakim FT; Castiello L; Sabatino M; Leitman SF; Mariotti J; Gea-Banacloche JC; Sportes C; Hardy NM; Hickstein DD; Pavletic SZ; Rowley S; Goy A; Donato M; Korngold R; Pecora A; Levine BL; June CH; Gress RE; Bishop MR
    Blood; 2013 Apr; 121(15):2864-74. PubMed ID: 23426943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation.
    Song Y; Zhu Y; Hu B; Liu Y; Lin D; Jin Z; Yin Z; Dong C; Wu D; Liu H
    Front Immunol; 2020; 11():558143. PubMed ID: 33178187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplant conditions determine the contribution of homeostatically expanded donor CD8 memory cells to host lymphoid reconstitution following syngeneic HCT.
    Keith MR; Levy RB
    Exp Hematol; 2007 Aug; 35(8):1303-15. PubMed ID: 17553613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.
    Alyea EP; Canning C; Neuberg D; Daley H; Houde H; Giralt S; Champlin R; Atkinson K; Soiffer RJ
    Bone Marrow Transplant; 2004 Jul; 34(2):123-8. PubMed ID: 15133487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
    Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
    Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
    Ho VT; Kim HT; Kao G; Cutler C; Levine J; Rosenblatt J; Joyce R; Antin JH; Soiffer RJ; Ritz J; Avigan D; Alyea EP
    Am J Hematol; 2014 Dec; 89(12):1092-6. PubMed ID: 25132538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
    Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
    Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
    Front Immunol; 2019; 10():1997. PubMed ID: 31507601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.